Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $74.29, down 3.62% on the session, giving a market capitalisation of $3.20B. On trailing twelve-month figures it carries a trailing P/E of -68.16, a net margin of -7.7%. Its beta of 0.54 implies it has historically moved less than the broad market.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Tarsus Pharmaceuticals, Inc. is most often compared with the following Healthcare names: